CytoSorbents says Q3 operating cash flow reaches breakeven excluding restructuring payments
CTSO•CytoSorbents reported third-quarter 2026 operating cash flow of about $43,000 excluding $251,000 in restructuring payments. Total cash burn was about $200,000, cash and restricted cash totaled $5.7 million, and operating loss narrowed 59% to $1.2 million.
1. Cash flow and operating loss
CytoSorbents reported third-quarter 2026 positive operating cash flow of approximately $43,000, excluding approximately $251,000 in restructuring payments. Total cash burn, including those payments, was approximately $200,000, while cash, cash equivalents and restricted cash totaled approximately $5.7 million. Operating loss narrowed 59% to $1.2 million, reflecting lower expenses and improved gross margin.




